Berkshire Hathaway raises new CEO’s salary to $25 million

Berkshire Hathaway raised CEO Greg Abel's salary to $25 million after he became CEO on January 1, a marked increase over Warren Buffett's long-standing $100,000 annual pay; Abel previously received $21 million in 2024, $20 million in 2023 and $16 million plus a $3 million bonus in 2022. Vice Chairman Ajit Jain received the same compensation amounts from 2022–2024; Abel owns about $171 million of Berkshire stock and in 2022 sold a 1% stake in Berkshire Hathaway Energy to Berkshire for $870 million. Buffett remains chairman of the more than $1 trillion conglomerate, and the pay change formalizes senior executive compensation without materially altering Berkshire’s fundamentals or likely valuation impact.

Analysis

Market structure: The $25m pay raise chiefly benefits senior management (Greg Abel, Ajit Jain) and signals a move toward market-competitive executive compensation; economically the increase is immaterial to a >$1tn enterprise (order of magnitude <0.01% of market cap) but symbolically shifts investor expectations away from Buffett-era austerity. Direct losers are sentiment-driven retail holders and Buffett-brand purists who may reprice governance risk; operational competitive dynamics across Berkshire’s businesses (insurance, rail, utilities) are unchanged in the near term.

Risk assessment: Tail risks include a governance backlash (proxy fights, litigation) or a reputational shock that could trigger a transient 1–5% re-rating in BRK.B within days-weeks; long-term risks are low unless compensation structures change to reduce capital allocation discipline. Hidden dependencies: Abel’s alignment (owns ~$171m) and prior sale of his BHE stake suggest future bespoke compensation (cash vs equity) that could alter free cash flow patterns. Key catalysts: 2025 proxy/10-K disclosures and any material change to incentive metrics over the next 90–180 days.

Trade implications: For patient investors, modestly overweight BRK.B (establish 1–2% portfolio long in BRK.B) over 6–12 months—add on >3% pullbacks; alternatively, buy 9–12 month LEAP calls (BRK.B Jan 2027 5–10% OTM) for asymmetric upside while keeping max allocation to options <0.5% portfolio. Use a relative-value pair: long BRK.B / short SPY sized to equal beta to isolate conglomerate-specific re-rating risk; if governance noise spikes and BRK.B gaps down >4% in 7 days, buy 60-day puts to hedge.

Contrarian angles: The market underestimates that this normalization of pay could professionalize succession and improve M&A/talent acquisition, which could support a 0.5–1.0x multiple expansion over 12–36 months if EPS momentum returns. Consensus reaction may be overdone short-term; monitor insider sales (threshold: >$50m aggregate in 90 days) and 2025 comp metrics—if both occur, materially reduce exposure within 30 days.

Key Decisions for Investors

• Establish a 1–2% portfolio long position in BRK.B (ticker BRK.B) within 10 trading days; scale in and add on any intraday weakness >3%, target 6–12 month hold for potential multiple re-rating.
• Buy BRK.B LEAP calls with 9–12 month expiries (e.g., Jan 2027 strikes ~5–10% OTM) sized to 0.3–0.5% of portfolio for leveraged upside while keeping downside limited to option premium.
• Implement a beta-neutral pair: long BRK.B and short SPY sized to equal market beta to isolate conglomerate-specific upside; rebalance monthly and close within 6–12 months unless governance catalysts materialize.
• Prepare tactical protection: if BRK.B declines >4% within a 7-day window, purchase 60-day put protection equal to 0.5–1% portfolio exposure; if insiders disclose >$50m in sales in 90 days or 2025 proxy reveals dilutive equity plans, reduce BRK.B exposure to <0.5% within 30 days.